Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 7, 2014, Pages 1497-1506

  Peng, Lei ^a   Feng, Lan ^a   Yuan, Hong ^b   Benhabbour, S Rahima ^a   Mumper, Russell J ^a,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bioluminescence; Docetaxel conjugate; Lipid nanoparticles; Micro PET CT; Orthotopic lung cancer model

Indexed keywords

BIOLOGICAL ORGANS; BIOLUMINESCENCE; CELLS; CYTOLOGY; DISEASES; MAMMALS; NANOPARTICLES; PHOSPHORESCENCE; TANTALUM COMPOUNDS;

BIOLUMINESCENCE IMAGING; DOCETAXEL; INTRAVENOUS ADMINISTRATION; LIPID NANOPARTICLES; LUNG CANCER; MICRO PETS; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL;

DRUG PRODUCTS;

2' (2 BROMOHEXADECANOYL)DOCETAXEL; DOCETAXEL; LUCIFERASE; NANOCONJUGATE; PALMITIC ACID DERIVATIVE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; NANOPARTICLE; TAXOID;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER MODEL; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; MOUSE MODEL; NANOMEDICINE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; STAINING; SURVIVAL TIME; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; MULTIMODAL IMAGING; NUDE MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; LUNG NEOPLASMS; MICE; MICE, NUDE; MULTIMODAL IMAGING; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84912150775     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.03.016     Document Type: Article

References (34)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Kuo T.H. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res 1993, 13:627-630.
3. Wilmanns C. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992, 52:98-104.
4. McLemore T.L., Liu M.C., Blacker P.C., Gregg M., Alley M.C., Abbott B.J., et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 1987, 47:5132-5140.
5. Zou Y., Fu H., Ghosh S., Farquhar D., Klostergaard J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non small cell lung cancer xenograft models. Clin Cancer Res 2004, 10:7382-7391.
6. Hasenpusch G., Pfeifer C., Aneja M.K., Wagner K., Reinhardt D., Gilon M., et al. Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS One 2011, 6:e20760.
7. Onn A., Isobe T., Itasaka S., Wu W., O'Reilly M.S., Ki Hong W., et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003, 9:5532-5539.
8. Podesta J.E., Al-Jamal K.T., Herrero M.A., Tian B., Ali-Boucetta H., Hegde V., et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009, 5:1176-1185.
9. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2009, 36:6251-6266.
10. Ramanlal Chaudhari K., Kumar A., Megraj Khandelwal V.K., Ukawala M., Manjappa A.S., Mishra A.K., et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release 2012, 158:470-478.
11. Naik S., Patel D., Chuttani K., Mishra A.K., Misra A. In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. Nanomedicine 2012, 8:951-962.
12. Venishetty V.K., Komuravelli R., Kuncha M., Sistla R., Diwan P.V. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine 2013, 9:111-121.
13. Ungaro F., Conte C., Ostacolo L., Maglio G., Barbieri A., Arra C., et al. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. Nanomedicine 2012, 8:637-646.
14. Feng L., Wu H., Ma P., Mumper R.J., Benhabbour S.R. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo. Int J Nanomedicine 2011, 6:2545-2556.
15. Ali S., Ahmad I., Peters A., Masters G., Minchey S., Janoff A., et al. Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities. Anti-Cancer Drugs 2001, 12:117-128.
16. Foltz C.J., Ullman-Cullere M. Guidelines for assessing the health and condition of mice. Lab Animal 1999, 28:28-32.
17. Huynh L., Leroux J.-C., Allen C. Enhancement of docetaxel solubility via conjugation of formulation-compatible moieties. Org Biomol Chem 2009, 7:3437-3446.
18. Feng L., Benhabbour S.R., Mumper R.J. Oil-filled lipid nanoparticles containing 2'-(2-bromohexadecanoyl)-docetaxel for the treatment of breast cancer. Adv Healthc Mater 2013, 10.1002/adhm.201300017.
19. Dong X., Mattingly C.A., Tseng M., Cho M., Adams V.R., Mumper R.J. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 2009, 72:9-17.
20. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009, 5:151-161.
21. Ma P., Benhabbour S.R., Feng L., Mumper R.J. 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett 2013, 334:253-262.
22. Madero-Visbal R.A., Colon J.F., Hernandez I.C., Limaye A., Smith J., Lee C.M., et al. Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer. Surg Oncol 2012, 21:23-29.
23. Vertrees R.A., Deyo D.J., Quast M., Lightfoot K.M., Boor P.J., Zwischenberger J.B. Development of a human to murine orthotopic xenotransplanted lung cancer model. J Invest Surg 2000, 13:349-358.
24. Kang Y., Omura M., Suzuki A., Oka T., Nakagami Y., Cheng C., et al. Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer. Cancer Sci 2006, 97:996-1001.
25. Wu S., Kasim V., Kano M.R., Tanaka S., Ohba S., Miura Y., et al. Transcription factor YY1 contributes to tumor growth by stabilizing hypoxia factor HIF-1α in a p53-independent manner. Cancer Res 2013, 73:1787-1799.
26. Ahmed A.U., Schmidt R.L., Park C.H., Reed N.R., Hesse S.E., Thomas C.F., et al. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 2008, 100:1606-1629.
27. Kim S.-L., Kim E.-M., Cheong S.-J., Lee C.-M., Kim D.W., Jeong H.-J., et al. The effect of PPAR-γ agonist on 18F-FDG uptake in tumor and macrophages and tumor cells. Nucl Med Biol 2009, 36:427-433.
28. Ong L.C., Jin Y., Song I.C., Yu S., Zhang K., Chow P.K. 2-[18F]-2-Deoxy-d-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008, 49:1145-1153.
29. Guo R., Liang S., Ma Y., Shen H., Xu H., Li B. Evaluation of biodistribution and antitumor effects of (188)Re-rhk5 in a mouse model of lung cancer. Oncol Lett 2011, 2:865-870.
30. Machtay M., Duan F., Siegel B.A., Snyder B.S., Gorelick J.J., Reddin J.S., et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 Trial. J Clin Oncol 2013, 31:3823-3830.
31. Gu Y.J., Cheng J.P., Man C.W.Y., Wong W.T., Cheng S.H. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 2012, 8:204-211.
32. Yan F., Zhang C., Zheng Y., Mei L., Tang L.N., Song C.X., et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010, 6:170-178.
33. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54:759-779.
34. Dong X. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009, 69:3918-3926.